Response to Comments: MolDX: Oncotype DX AR-V7 Nucleus Detect for Men with Metastatic Castrate Resistant Prostate Cancer (MCRPC)

This document records the response to comments and administrative timeline for MolDX: Oncotype DX AR‑V7 Nucleus Detect for men with metastatic castrate resistant prostate cancer (DL37746). The comment period ran 2018-06-07 to 2018-08-14, the notice period ran 2019-01-15 to 2019-03-01, and the local coverage determination became final on 2019-03-02. No clinical coverage criteria, limitations, documentation requirements, or frequency limits are specified in this document.